

# CNS Cancer™

U P D A T E

Conversations with Oncology Investigators  
Bridging the Gap between Research and Patient Care

## Select Publications

A phase III, randomised, parallel group, multi-centre study in recurrent glioblastoma patients to compare the efficacy of cediranib [RECENTIN™, AZD2171] monotherapy and the combination of cediranib with lomustine to the efficacy of lomustine alone. **NCT00777153**

A prospective, multi-center trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM. **NCT00916409**

Barker CA et al. **Hepatic enzyme-inducing antiepileptic drug use is not associated with survival in Glioblastoma multiforme.** *Proc SNO* 2010;Abstract NO-01.

Chamberlain MC. **Bevacizumab for the treatment of recurrent glioblastoma.** *Clin Med Insights Oncol* 2011;5:117-29. **Abstract**

Chamberlain MC. **Temozolomide: Therapeutic limitations in the treatment of adult high-grade gliomas.** *Expert Rev Neurother* 2010;10(10):1537-44. **Abstract**

Chamberlain MC, Johnston SK. **Salvage therapy with single agent bendamustine for recurrent glioblastoma.** *J Neurooncol* 2011;[Epub ahead of print]. **Abstract**

Chinot OL et al. **AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.** *Proc ASCO* 2011;Abstract TPS136.

Chinot OL et al. **AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.** *Adv Ther* 2011;28(4):334-40. **Abstract**

Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme — A randomized Phase III study. **NCT00006353**

Correa DD et al. **Cognitive functions in primary CNS lymphoma after single or combined modality regimens.** *Neuro Oncol* 2011;[Epub ahead of print]. **Abstract**

De Groot JF et al. **Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601.** *Proc ASCO* 2008;Abstract 2020.

Fink J et al. **Pseudoprogression: Relevance with respect to treatment of high-grade gliomas.** *Curr Treat Options Oncol* 2011;12(3):240-52. **Abstract**

Friedman HS et al. **Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.** *J Clin Oncol* 2009;27(28):4733-40. **Abstract**

Jansen M et al. **Molecular pathology in adult gliomas: Diagnostic, prognostic, and predictive markers.** *Lancet Neurol* 2010;9(7):717-26. **Abstract**

Lai A et al. **Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with new diagnosed glioblastoma multiforme.** *J Clin Oncol* 2011;29(2):142-8. **Abstract**

Lutz K et al. **Neuroradiological response criteria for high-grade gliomas.** *Clin Neuroradiol* 2011;[Epub ahead of print]. **Abstract**

Narayana A et al. **A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.** *J Neurosurg* 2011;[Epub ahead of print]. **Abstract**

Ngwenya LB, Chiocca EA. **Extent of resection.** *J Neurosurg* 2011;115(1):1-2. **Abstract**

Phase III double-blind placebo-controlled trial of conventional concurrent chemoradiation and adjuvant temozolomide plus bevacizumab versus conventional concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma. **NCT00884741**

Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. **NCT00304031**

Raizer JJ et al. **A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.** *Cancer* 2010;116(22):5297-305. **Abstract**

Reardon DA et al. **A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.** *J Natl Compr Canc Netw* 2011;9(4):414-27. **Abstract**

Rosati A et al. **Efficacy and safety of levetiracetam in patients with glioma: A clinical prospective study.** *Arch Neurol* 2010;67(3):343-6. **Abstract**

Sampson JH et al. **Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.** *Neuro Oncol* 2011;13(3):324-33. **Abstract**

Sanai N et al. **An extent of resection threshold for newly diagnosed glioblastomas.** *J Neurosurg* 2011;115(1):3-8. **Abstract**

Sherman JH et al. **Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.** *J Neurosurg* 2011;114(6):1617-21. **Abstract**

Wick W et al. **Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.** *J Clin Oncol* 2010;28(7):1168-74. **Abstract**